By Fineline Cube 
China-based Acotec Scientific Holdings Ltd (HKG: 6669) has received marketing approval from China’s National Medical Products Administration (NMPA) for its paclitaxel-coated balloon dilatation catheter for vertebral artery applications, AcoArt Verbena. This marks a significant milestone in the company’s product portfolio.
Advanced Technology and Indications
AcoArt Verbena utilizes advanced drug-coating technology to enhance coating stability and optimize drug delivery. This innovation improves drug retention and tissue absorption rates. As the world’s first drug-coated balloon specifically designed for vertebral arteries, AcoArt Verbena is indicated for percutaneous transluminal angioplasty (PTA) in patients with symptomatic extracranial vertebral artery stenosis (≥70% stenosis at the vertebral artery origin) and recurrent symptoms in the vertebrobasilar territory despite medical therapy.
Clinical Performance
Clinical trials have demonstrated AcoArt Verbena’s excellent safety profile. It showed significantly lower 12-month target lesion restenosis rates compared to stents, highlighting its clinical advantages.-Fineline Info & Tech